ADOCIA
ShareCopied to clipboardADOCIA is a company. It is a public company in Lyon, France. It was founded in 2005 and its current CEO is Olivier Soula. It is part of the Health Care sector, specifically in the Biotechnology industry.
Key facts
- city: Lyon
- country: France
- employees: 78 people
- revenues: 6.6M $
- company type: public
- sector: Health Care
- industry: Biotechnology
- foundation year: 2005
- CEO: Olivier Soula
- ESG score: 69.87 / 100
See more facts
Extract data
Download datasets about ADOCIA:
Dataset of stocks from ADOCIA:
ADOCIA is one of the companies in France, companies in Biotechnology, companies in Health Care, companies in Lyon and 3,456,808 companies in our database.
Talking Points
- Adocia • Innovative medicine for everyone everywhere
- Adocia is a clinical-stage biotechnology company specialized in the development of innovative treatments for diabetes and obesity.
- Adocia is a clinical stage biopharmaceutical company focused on diabetes treatment and other metabolic diseases with innovative formulations of proteins.
- "Innovative medicine for everyone, everywhere" Listed on the Euronext stock market, Adocia is a clinical-stage biotech company specialized in the...
- Adocia SA, a clinical-stage biotechnology company, researches and develops formulations of pre-approved therapeutic proteins and peptides for the treatment of diabetes and other metabolic diseases. Its proprietary BioChaperone technological platform is designed and developed to optimize the performance of therapeutic proteins. The company's clinical product pipeline includes insulin formulations, such as BioChaperone Lispro U100 and U200, which are ultra-rapid formulations based on rapid insulin lispro; BioChaperone Combo, a combination of acting insulin glargine and rapid-acting insulin lispro; BioChaperone LisPram, a combination of prandial insulin with pramlintide; and BioChaperone Glucagon, an aqueous formulation of human glucagon for the treatment of hypoglycemia, as well as M1Pram, a metabolite of insulin glargine and pramlintide. Its preclinical pipeline includes bi-hormonal products, which include BioChaperone AsPram, which is a combination of rapid insulin aspart with pramlintide; and BioChaperone Glargine Liraglutidea, which is a fixed combination of insulin glargine with an analogue of the GLP-1 receptor. In addition, the company's preclinical pipeline includes multihormonal products for the treatment of obesity, including BioChaperone GluExe, which is a combination of glucagon and exenatide; PramExe, which is a combination of pramlintide and exenatide; and BioChaperone PramGluExe, which is a triple combination of pramlintide, glucagon and exenatide. It has a strategic alliance with Tonghua Dongbao Pharmaceutical Co., Ltd. to develop and commercialize BioChaperone Lispro and BioChaperone Combo in China and other Asian and Middle Eastern territories. The company was incorporated in 2005 and is headquartered in Lyon, France.